Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

1.

Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study.

Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA.

J Thorac Oncol. 2012 May;7(5):919-22. doi: 10.1097/JTO.0b013e31824de0d6.

PMID:
22722792
[PubMed - indexed for MEDLINE]
2.

Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.

Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M.

Clin Genitourin Cancer. 2007 Sep;5(6):379-85.

PMID:
17956710
[PubMed - indexed for MEDLINE]
3.

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.

Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, Reddy SA, Davis D, Zhang Y, Wolff RA, Abbruzzese JL.

BMC Cancer. 2010 Jul 14;10:368. doi: 10.1186/1471-2407-10-368.

PMID:
20630061
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors.

Soria JC, Shepherd FA, Douillard JY, Wolf J, Giaccone G, Crino L, Cappuzzo F, Sharma S, Gross SH, Dimitrijevic S, Di Scala L, Gardner H, Nogova L, Papadimitrakopoulou V.

Ann Oncol. 2009 Oct;20(10):1674-81. doi: 10.1093/annonc/mdp060. Epub 2009 Jun 23.

PMID:
19549709
[PubMed - indexed for MEDLINE]
Free Article
5.

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ; North Central Cancer Treatment Group.

J Clin Oncol. 2005 Aug 10;23(23):5294-304. Epub 2005 Jul 5.

PMID:
15998902
[PubMed - indexed for MEDLINE]
Free Article
6.

Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer.

Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, Bepler G.

J Clin Oncol. 2008 Mar 1;26(7):1135-41. doi: 10.1200/JCO.2007.14.3685.

PMID:
18309949
[PubMed - indexed for MEDLINE]
Free Article
7.

Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199).

Tinker AV, Ellard S, Welch S, Moens F, Allo G, Tsao MS, Squire J, Tu D, Eisenhauer EA, MacKay H.

Gynecol Oncol. 2013 Aug;130(2):269-74. doi: 10.1016/j.ygyno.2013.05.008. Epub 2013 May 11.

PMID:
23672928
[PubMed - indexed for MEDLINE]
8.

Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.

Sun Y, Rha S, Lee SH, Guo J, Ueda T, Qin S, Naito S, Cincotta M, Tokushige K, Akaza H.

Jpn J Clin Oncol. 2012 Sep;42(9):836-44. doi: 10.1093/jjco/hys110. Epub 2012 Jul 26.

PMID:
22844126
[PubMed - indexed for MEDLINE]
Free Article
9.

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, Provencher DM, Gotlieb WH, Hoskins PJ, Ghatage P, Tonkin KS, Mackay HJ, Mazurka J, Sederias J, Ivy P, Dancey JE, Eisenhauer EA.

J Clin Oncol. 2011 Aug 20;29(24):3278-85. doi: 10.1200/JCO.2010.34.1578. Epub 2011 Jul 25.

PMID:
21788564
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas.

Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL.

Br J Cancer. 2006 Nov 6;95(9):1148-54. Epub 2006 Oct 10.

PMID:
17031397
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM Jr, Morton RF, Schild SE, Jett JR, Adjei AA.

Ann Oncol. 2005 Nov;16(11):1811-6. Epub 2005 Aug 8.

PMID:
16087693
[PubMed - indexed for MEDLINE]
Free Article
12.

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.

Ludovini V, Bianconi F, Pistola L, Chiari R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A, Flacco A, Baldelli E, Iacono D, Mameli MG, Cavaliere A, Crinò L.

J Thorac Oncol. 2011 Apr;6(4):707-15. doi: 10.1097/JTO.0b013e31820a3a6b.

PMID:
21258250
[PubMed - indexed for MEDLINE]
13.

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Chan S, Scheulen ME, Johnston S, Mross K, Cardoso F, Dittrich C, Eiermann W, Hess D, Morant R, Semiglazov V, Borner M, Salzberg M, Ostapenko V, Illiger HJ, Behringer D, Bardy-Bouxin N, Boni J, Kong S, Cincotta M, Moore L.

J Clin Oncol. 2005 Aug 10;23(23):5314-22. Epub 2005 Jun 13.

PMID:
15955899
[PubMed - indexed for MEDLINE]
Free Article
14.

A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).

Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH; Eastern Cooperative Oncology Group (E1500).

J Thorac Oncol. 2007 Nov;2(11):1036-41.

PMID:
17975496
[PubMed - indexed for MEDLINE]
15.

Expression of the mammalian target of rapamycin pathway markers in lung adenocarcinoma and squamous cell carcinoma.

Kim HS, Kim GY, Lim SJ, Kim YW.

Pathobiology. 2012;79(2):84-93. doi: 10.1159/000334340. Epub 2012 Jan 27.

PMID:
22286903
[PubMed - indexed for MEDLINE]
16.

Analysis of PTEN and HIF-1alpha and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-alpha.

Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G.

Cancer. 2009 Aug 15;115(16):3651-60. doi: 10.1002/cncr.24438.

PMID:
19526589
[PubMed - indexed for MEDLINE]
Free Article
17.

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial.

N Engl J Med. 2007 May 31;356(22):2271-81.

PMID:
17538086
[PubMed - indexed for MEDLINE]
Free Article
18.

A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naïve castration-resistant prostate cancer.

Kruczek K, Ratterman M, Tolzien K, Sulo S, Lestingi TM, Nabhan C.

Br J Cancer. 2013 Oct 1;109(7):1711-6. doi: 10.1038/bjc.2013.530. Epub 2013 Sep 5.

PMID:
24008662
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group.

Shepherd FA, Dancey J, Arnold A, Neville A, Rusthoven J, Johnson RD, Fisher B, Eisenhauer E.

Cancer. 2001 Aug 1;92(3):595-600.

PMID:
11505404
[PubMed - indexed for MEDLINE]
20.

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.

PMID:
18215105
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk